Clinical trials: Glymphatic System
Alzheimer Disease
Pharmacological Enhancement of Glymphatic Function in Humans
Alzheimer's disease is linked in part to the buildup of harmful proteins in the brain, including amyloid and tau. Most current treatments aim to remove these proteins directly.
- Trial name
- NCT07432997
- Testing
- Dexmedetomidine, Dexmedetomidine and Midodrine
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Applied Cognition
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Yoga-based, Movement Therapy Device as Noninvasive Glymphatic Clearance Augmentation in Alzheimer's Disease.
This clinical trial evaluates a yoga-based intervention delivered through a powered therapeutic device designed to guide breathing and body movements.
- Trial name
- ReGlyde (NCT06989242)
- Testing
- Yoga-Based Therapeutic Device (incorporating guided breathing and movement)
- Where
- 3 sites in Czechia, Slovakia
- Volunteers
- 60 people
- Sponsor
- CIATRIX, INC.